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OBJECTIVE — Tocomparetwosubcutaneousinsulinstrategiesforglycemicmanagementof
hyperglycemia in non–critically ill hospitalized patients with diabetes during enteral nutrition
therapy (ENT).
RESEARCH DESIGN AND METHODS — Fifty inpatients were prospectively random-
ized to receive sliding-scale regular insulin (SSRI) alone (n  25) or in combination with insulin
glargine (n  25). NPH insulin was added for persistent hyperglycemia in the SSRI group
(glucose 10 mmol/l).
RESULTS — GlycemiccontrolwassimilarintheSSRIandglarginegroups(meanSDstudy
glucose 8.9  1.6 vs. 9.2  1.6 mmol/l, respectively; P  0.71). NPH insulin was added in 48%
oftheSSRIgroupsubjects.Therewerenogroupdifferencesinfrequencyofhypoglycemia(1.3
4.1 vs. 1.1  1.8%; P  0.35), total adverse events, or length of stay.
CONCLUSIONS — Both insulin strategies (SSRI with the addition of NPH for persistent
hyperglycemia and glargine) demonstrated similar efﬁcacy and safety in non–critically ill hos-
pitalized patients with type 2 diabetes during ENT.
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H
yperglycemia is a commonly en-
countered complication of inpa-
tient enteral nutrition therapy
(ENT) (1,2). In one study, 34% of sub-
jects receiving ENT experienced blood
glucose levels11.1 mmol/l (2). This de-
gree of hyperglycemia is associated with
adverse patient outcomes and prolonged
hospital length of stay (LOS) (3–5).
Although several subcutaneous insu-
lin regimens are proposed for managing
patients during ENT in noncritical care
units, there are no studies comparing
thesestrategies(4).Thisresultsinthepre-
scribing of insulin therapy according to
clinicianpreferenceoftenwithoutachiev-
ing desired glycemic targets (6,7).
The primary aim of this study was to
compare the effect of administration of
sliding-scale regular insulin (SSRI) alone
with that of administration of insulin
glargineincombinationwithSSRIongly-
cemic control, adverse events, and hospi-
tal LOS during inpatient ENT.
RESEARCH DESIGN AND
METHODS— This open-label, ran-
domized clinical trial was approved by
theinstitutionalreviewboard.Allpatients
provided written consent.
Fifty inpatients meeting criteria for
inpatient diagnosis of diabetes with two
or more blood glucose measures 7.2
mmol/l during ENT were randomized to
the SSRI (n  25) or glargine (n  25)
groups. The SSRI was administered every
4–6haccordingtoresultsofbedsideglu-
cose monitoring (LifeScan, Milpitas, CA)
using a previously published regimen (8)
(see Appendix A in the online appendix
availableathttp://care.diabetesjournals.org/
cgi/content/full/dc08-1436/DC1). Patients
who were able to eat during ENT had glu-
cose monitoring and SSRI timed before
meals and bedtime.
The goal in both groups was to
achieveglucoselevelsbetween5.6and10
mmol/l while avoiding hypoglycemia.
Bedside glucose results were reviewed on
a daily basis by one of the investigators,
who adjusted insulin therapy according
to prespeciﬁed algorithms (see online ap-
pendices B and C). NPH insulin was
added in the SSRI group for persistent
glucose levels 10 mmol/l. Hypoglyce-
mia (glucose 3.9 mmol/l) was treated
according to a previously published
guideline (9) and prompted decreases in
frequency or intensity of SSRI or basal in-
sulin. Glucose results are presented as
overall study mean, daily mean, mean
peak, and nadir values. Each subject
had a maximum of six glucose values
per 24 h. When more than one glucose
value was measured in a 4-h interval,
the maximum or minimum value de-
ﬁned that time period.
Additionaldatacollectedincludedin-
sulin type and dose, morning triglyce-
rides at randomization and study
completion, ENT formula and delivery
rate,severity-of-illnessscores(10),Charl-
son score (11), adverse events (Table 1),
and LOS. Hypoglycemia frequency is re-
ported as percentage of patient-days with
one or more event and percentage of all
glucose values 3.9 mmol/l.
Statistical analyses were performed
usingSAS(version9.1).Theintention-to-
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comparisonsofcontinuousdatawithStu-
dent’s t test or Wilcoxon’s rank-sum test
and of categorical data with the 
2 or
Fisher’s exact test. Paired Student’s t tests
wereperformedtocomparewithin-group
differences.
RESULTS— The clinical data for each
group are summarized in Table 1. The
mean duration of participation was 6.0 
2.2 days (range 1–8) in both groups. No
group differences were observed in glyce-
mic measures or triglycerides during the
study (Table 1).
Twelve patients in the SSRI group re-
quired the continuation (n  2) or addi-
tion (n  10; days 2–5) of NPH insulin.
These patients had higher baseline glu-
cose levels (11.3  3.1 vs. 8.5  1.4
mmol/l; P  0.011) and severity-of-
illness scores (115  20 vs. 96  24; P 
0.04), required more insulin (47  29 vs.
9  10 units/day; P  0.01), and were
morelikelytohavediabetesprecedingad-
mission (67 vs. 46% in the glargine
group). Total daily insulin doses were
similar between the SSRI and glargine
groups (Table 1).
Decisions regarding type of ENT for-
mula were made by the primary team and
nutrition service. Several patients re-
ceived more than one type of ENT for-
mula during this study, with variation in
the percentage of carbohydrate calories
(34–65%). The majority of patients (n 
29) received formulations containing
50% carbohydrate. With the exception
of more days with a body temperature
100.4°F in the SSRI group, there were
nodifferencesinadverseevents(Table1).
CONCLUSIONS — This is the ﬁrst
randomized study comparing subcutane-
ous insulin regimens in non–critically ill
inpatients with diabetes receiving ENT.
Similar levels of glycemic control were
achieved in each group, suggesting that
earlyadditionofbasalinsulinwithcareful
attention to glycemic control is effective
and safe in these patients.
The level of glycemic control achieved
in this study is similar to that achieved in a
prior report where subcutaneous insulin
doses were based on an initial dose-
ﬁnding regimen with intravenous insulin
in patients receiving ENT (12). Although
intravenous insulin may offer advantages
of rapid attainment of glycemic control
during dose-deﬁning periods, many hos-
pitals do not permit this on general nurs-
ing units. In addition, the rate and
duration of ENT can change frequently,
requiring ongoing adjustments in sched-
uled insulin (13).
Concern for hypoglycemia with basal
insulin in patients receiving ENT contrib-
utes to an overdependence on SSRI regi-
mens (6). Although SSRI was effective in
some patients in this and previous re-
ports, any missed dose can result in hy-
perglycemia (14,15). The subjects who
Table 1—Clinical data for glargine and SSRI groups
Glargine SSRI P
n 25 25
Age (years) 67  10 63  10 0.20
Sex (female) 36 44 0.56
BMI (kg/m
2) 29.1  5.8 26.9  1.7 0.22
Previous diabetes 11 (44) 14 (56) 0.40
LOS (days) 24.2  18.2 23.8  18.8 0.85
Severity-of-illness score 110  25 105  24 0.27
Charlson score 4.9  3.3 3.6  3.4 0.17
Primary diagnosis
GI cancer/mass 13 13
Esophageal tear/rupture 3 1
Pancreatitis 1 3
Head and neck cancer 2 1
Other 6 7
Glycemic data
Entry glucose (mmol/l) 9.8  2.7 9.9  2.7
Study day 1 9.6  2.3 9.6  2.5 0.59
Study day 2 9.7  2.6 9.2  2.3 0.52
Study day 3 9.6  2.3 9.2  2.4 0.57
Study day 4 9.4  2.1 9.3  2.4 0.98
Study day 5 8.8  1.8 9.1  1.9 0.66
Study day 6 8.6  1.4 8.4  1.6 0.62
Study day 7 8.8  1.8 7.8  1.3 0.27
Study day 8 7.8  1.8 8.0  1.4 0.48
Mean study glucose (mmol/l) 9.1  1.6 8.9  1.6 0.71
Mean peak glucose (mmol/l) 11.4  2.7 11.5  2.9 0.95
Mean nadir glucose (mmol/l) 6.9  1.6 6.7  1.2 0.51
Hypoglycemia
Patient days 2.7 4.8 0.34
Blood glucose measures 1.3 1.1 0.35
Insulin
Total daily dose (units) 27.2  20.5 27.0  28.5 0.33
SSRI (units/day) 11.3  9.3 15.7  12.4 0.22
Total daily dose (units   kg
1   day
1) 0.33  0.26 0.33  0.33
Basal insulin (%) 66.9  13.8 24.0  28.7 0.001
NPH and SSRI (%)* NA 55.1  7.0 0.45†
Triglycerides (mmol/l)
Baseline 1.6  0.5 1.6  0.8 0.52
End of study 1.6  0.5 1.6  0.5 0.95
Adverse events (n)
Body temperature 100.4°F (days) 0 8 0.003
Antibiotic use (days) 64 74 0.13
Arrythmias 1 2 1.0
Pulmonary emboli 2 1 0.49
Deep venous thrombosis 2 0 1.0
Wound infection 1 0
Respiratory symptoms 2 2 1.0
Cardiac arrest 0 1 1.0
Liver abscess 1 0 1.0
Data are percent, n (%), or means  SD unless otherwise indicated. *n  12. †Compared with the glargine
group. GI, gastrointestinal; NA, not available.
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lower glucose levels at randomization
and were less likely to have preadmis-
siondiabetes.AdministrationofanSSRI
may, thus, be a reasonable initial strat-
egy for selected patients receiving ENT;
however, it is important to initiate
scheduled insulin once glucose levels
exceed 10 mmol/l (7).
This study has important implica-
tions for clinical practice. More than 50%
of study patients had no prior history of
diabetes, underscoring the importance of
monitoring glucose levels with ENT initi-
ation to allow identiﬁcation of those re-
quiring insulin (3). These ﬁndings
provide a guide for insulin therapy in in-
patientswhodevelophyperglycemiadur-
ing ENT.
The small number of patients is an
importantlimitationtowidespreadappli-
cation of this study. Although the glyce-
mic control achieved was not optimal,
frequent changes in the rate and type of
ENT were contributing factors. Patients
receiving ENT spend the majority of time
in a postprandial state, with altering rec-
ommendationsforglycemiccontrol(4,7).
Studies that investigate strategies for
safelyachievingspeciﬁedglycemictargets
during ENT in larger numbers of patients
are needed.
In conclusion, we demonstrated that
the majority of non–critically ill inpa-
tients will require basal insulin during
ENTtoachieveandmaintainareasonable
degree of glucose control. Although SSRI
maybeanacceptableinitialtherapyinthe
setting of mild hyperglycemia or in pa-
tients without prior diabetes, scheduled
insulin is required once a consistent insu-
lin requirement is demonstrated.
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